Analyst Price Targets — XGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 24, 2026 8:25 pm | — | Roth Capital | $8.00 | $4.52 | TheFly | Exagen initiated with a Buy at Roth Capital |
| May 12, 2026 11:35 am | — | BTIG | $8.00 | $3.98 | TheFly | Exagen price target lowered to $8 from $9 at BTIG |
| April 20, 2026 1:10 pm | — | Canaccord Genuity | $8.00 | $2.97 | TheFly | Exagen price target lowered to $8 from $10 at Canaccord |
| March 11, 2026 1:15 pm | — | UBS | $10.00 | $3.11 | TheFly | Exagen price target lowered to $10 from $12 at Craig-Hallum |
| March 10, 2026 7:38 pm | Mark Massaro | BTIG | $9.00 | $3.25 | StreetInsider | Exagen (XGN) PT Lowered to $9 at BTIG |
| February 17, 2026 12:15 pm | Mark Massaro | BTIG | $10.00 | $3.28 | TheFly | Exagen price target lowered to $10 from $15 at BTIG |
| October 27, 2025 10:50 am | — | Canaccord Genuity | $15.00 | $11.96 | TheFly | Exagen price target raised to $15 from $11 at Canaccord |
| October 14, 2025 10:36 am | — | KeyBanc | $15.00 | $11.04 | TheFly | Exagen price target raised to $15 from $12 at KeyBanc |
| July 30, 2025 12:55 pm | — | Cantor Fitzgerald | $10.00 | $8.63 | TheFly | Exagen price target raised to $10 from $7 at Cantor Fitzgerald |
| July 29, 2025 11:28 pm | — | KeyBanc | $12.00 | $8.45 | TheFly | Exagen upgraded to Overweight from Sector Weight at KeyBanc |
Latest News for XGN
Shares of Exagen Inc. (NASDAQ: XGN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation
Amplifon (OTCMKTS:AMFPF - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Analyst Ratings This is a breakdown of current ratings and
Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even.
Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XGN.
U.S. House Trading
No House trades found for XGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.